Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Becton Dickinson v. Quidel

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson v. Quidel: Firms reach settlement agreement on a patent infringement suit alleging that several Quidel products infringe on two Becton Dickinson patents for analytical chemistry tests ("The Gray Sheet" April 14, In Brief). Under the terms of the agreement Quidel will pay a cash license fee and royalties on net sales of the products beginning April 1, 1997. Quidel also will license its Q-Label technology to BD in exchange for royalties on future sales. Noting that it "has opportunities to mitigate the impact" of the additional expense through sales growth and improved margins, Quidel estimates that the annual cost of the settlement to the firm will be approximately $1.9 mil. Quidel continues to maintain that its products to not infringe the BD patents...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel